Aflibercept – July 2026

  • Brand names:
    • Eydenzelt®
  • Pharmaceutical Company:
    • CELLTRION HEALTHCARE AUSTRALIA PTY LTD
  • Condition/Indication: Branch retinal vein occlusion with macular oedema; Central retinal vein occlusion with macular oedema; Diabetic macular oedema; Subfoveal choroidal neovascularisation due to age-related macular degeneration
  • Meeting Date: July 2026
Public Summary Documents
Last updated
13 November 2026